Weight management · Prescription only
Tirzepatide
A dual GIP and GLP-1 receptor agonist studied for weight management and glycemic control, available after a licensed-provider evaluation.
Treatment length is confirmed at checkout after your provider approves treatment.
Beginning treatment does not create a prescription. A US-licensed provider reviews your intake first, and an order is only filled if they determine treatment is appropriate for you.
Treatment details
- Medication
- Tirzepatide
- Category
- Weight management
- Access
- Available after a licensed-provider evaluation
- Fulfillment
- Compounded by a US-licensed compounding pharmacy
- FDA status
- Compounded — not FDA-approved
- Shipping
- Discreet, United States only
$139.00 is a placeholder price pending final confirmation. Van Peptides does not compound, manufacture, or dispense medication itself.
What it is
Tirzepatide is a single peptide that activates two incretin receptors, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. That dual mechanism is what distinguishes it from single-agonist GLP-1 medications, and it has been studied for effects on appetite regulation, gastric emptying, and glycemic control (Jastreboff et al., New England Journal of Medicine, 2022). Outcomes are individual, and the size of any effect depends on the person, the dose a provider selects, and the lifestyle changes that accompany treatment.
Van Peptides does not sell tirzepatide over the counter. It is available after a licensed-provider evaluation, and any prescription that follows is compounded through a US-licensed compounding pharmacy rather than manufactured by Van Peptides itself.
The compounded tirzepatide dispensed through this pathway is not the same thing as an FDA-approved brand-name product. Compounded medications are prepared for an individual patient by a licensed pharmacy and are not reviewed by the FDA for safety, efficacy, or manufacturing quality. Our compounded medication disclosure explains what that means in practice.
What the literature has explored
The SURMOUNT-1 trial studied once-weekly tirzepatide in adults with obesity or overweight without diabetes. Over seventy-two weeks, participants on the highest studied dose experienced a mean change in body weight of roughly negative twenty-one percent, compared with roughly negative three percent on placebo (Jastreboff et al., New England Journal of Medicine, 2022). As with any trial figure, that describes a study population under study conditions rather than a predicted outcome for an individual.
The SURPASS program examined tirzepatide for glycemic control in type 2 diabetes and reported reductions in HbA1c across several comparator arms (FrÃas et al., New England Journal of Medicine, 2021). Whether any of that research applies to your situation is a question for a licensed provider who can review your history.
Individual results vary. A provider weighs the published evidence against your medical history, current medications, and goals before deciding whether a prescription is appropriate at all, and what it should look like if it is.
How the telehealth path works
- Complete a short online intake.
- A US-licensed provider reviews your history and speaks with you if appropriate.
- If clinically appropriate, a prescription is issued and routed to a US-licensed compounding pharmacy.
- The medication ships discreetly in the US, with dispensing instructions from the pharmacy.
Van Peptides is a technology platform. It does not diagnose, prescribe, compound, or dispense. Each step above is carried out by an independent US-licensed provider or a US-licensed compounding pharmacy.
Common questions
What is tirzepatide?
It is a dual GIP and GLP-1 receptor agonist studied for weight management and glycemic control, acting on appetite signaling and gastric emptying through two incretin pathways rather than one.
Who is a candidate?
That determination is made by a US-licensed provider after reviewing your intake and history; it is available after a licensed-provider evaluation, not a self-selected purchase.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved. FDA-approved brand-name tirzepatide products exist, but a compounded preparation is a different product and is not reviewed by the FDA.
How is it dispensed?
If a provider issues a prescription, it is compounded through a US-licensed compounding pharmacy and shipped directly to you.
What does it cost?
Placeholder plan pricing is $199 monthly, $549 for a three-month plan, and $999 for a six-month plan. Final pricing will be confirmed before this page goes live.
How is my privacy protected?
Intake information is handled under our HIPAA Notice of Privacy Practices; see our HIPAA notice for details.
What if it isn’t right for me?
A licensed provider may determine that tirzepatide is not appropriate for you, in which case they will discuss alternative options or next steps as part of your evaluation.